全文获取类型
| 收费全文 | 2639篇 |
| 免费 | 0篇 |
| 国内免费 | 1篇 |
专业分类
| 综合类 | 1篇 |
| 化学工业 | 14篇 |
| 金属工艺 | 1篇 |
| 建筑科学 | 2篇 |
| 能源动力 | 1篇 |
| 轻工业 | 6篇 |
| 水利工程 | 2篇 |
| 石油天然气 | 1篇 |
| 武器工业 | 1篇 |
| 一般工业技术 | 15篇 |
| 冶金工业 | 2586篇 |
| 原子能技术 | 2篇 |
| 自动化技术 | 8篇 |
出版年
| 2024年 | 2篇 |
| 2022年 | 2篇 |
| 2021年 | 1篇 |
| 2017年 | 2篇 |
| 2016年 | 1篇 |
| 2014年 | 2篇 |
| 2013年 | 3篇 |
| 2011年 | 4篇 |
| 2010年 | 4篇 |
| 2009年 | 3篇 |
| 2008年 | 3篇 |
| 2007年 | 1篇 |
| 2006年 | 1篇 |
| 2005年 | 1篇 |
| 2004年 | 4篇 |
| 2003年 | 6篇 |
| 2002年 | 1篇 |
| 2001年 | 1篇 |
| 2000年 | 2篇 |
| 1999年 | 78篇 |
| 1998年 | 797篇 |
| 1997年 | 461篇 |
| 1996年 | 284篇 |
| 1995年 | 146篇 |
| 1994年 | 136篇 |
| 1993年 | 153篇 |
| 1992年 | 26篇 |
| 1991年 | 32篇 |
| 1990年 | 30篇 |
| 1989年 | 39篇 |
| 1988年 | 35篇 |
| 1987年 | 30篇 |
| 1986年 | 25篇 |
| 1985年 | 29篇 |
| 1983年 | 7篇 |
| 1982年 | 16篇 |
| 1981年 | 13篇 |
| 1980年 | 15篇 |
| 1978年 | 7篇 |
| 1977年 | 58篇 |
| 1976年 | 175篇 |
| 1975年 | 2篇 |
| 1973年 | 1篇 |
| 1955年 | 1篇 |
排序方式： 共有2640条查询结果，搜索用时 0 毫秒
21.
RS Wallis P Nsubuga C Whalen RD Mugerwa A Okwera D Oette JB Jackson JL Johnson JJ Ellner 《Canadian Metallurgical Quarterly》1996,174(4):727-733
Macrophage activation and tumor necrosis factor-alpha (TNF-alpha) production are critical in tuberculosis immunity but may result in increased human immunodeficiency virus (HIV) expression and accelerated HIV disease progression in HIV-infected persons. Pentoxifylline inhibits expression of TNF-alpha and HIV. A double-blind, placebo-controlled study of adjunctive therapy with pentoxifylline (1800 mg/day) as a timed-release formulation was done in Ugandan HIV-infected patients with pulmonary tuberculosis. Subjects had early HIV disease (mean CD4 cell count, 380/microL) and did not receive other antiretroviral drugs. Pentoxifylline resulted in decreased plasma HIV RNA and serum beta 2-microglobulin and, in a subset of moderately anemic patients, improved blood hemoglobin levels. Trends were noted toward reduced TNF-alpha production in vitro and improved performance scores, but these did not reach statistical significance. No effect was noted on body mass, CD4 cell count, or survival. Additional studies of more potent TNF-alpha inhibitors in HIV-positive subjects with tuberculosis are warranted. 相似文献
22.
F Vincenti GM Danovitch JF Neylan RW Steiner MP Everson RS Gaston 《Canadian Metallurgical Quarterly》1996,61(4):573-577
The use of OKT3 as an immunosuppressive agent is accompanied by increased cytokine production and constellation of side effects collectively termed cytokine release syndrome (CRS). Pentoxifylline (PTF) inhibits synthesis of some cytokines, and has been shown to attenuate CRS when administered before OKT3. In this double-blinded, placebo-controlled study, 46 renal allograft recipients were randomized to receive either PTF (800 mg q 8 hr for at least 24 h) p.o. or placebo, along with methylprednisolone (7 mg/kg), diphenhydramine, and acetaminophen, prior to beginning OKT3 as therapy for acute rejection. Patients were observed, and symptoms scored semiquantitatively. Despite the presence of therapeutic PTF levels (721 +/- 726 ng/ml), the frequency and severity of side effects (fever, chills, headache, neurocortical symptoms, dyspnea, nausea, vomiting, diarrhea) did not differ between treatment groups. Likewise PTF did not affect renal function or immunologic response to OKT3, with similar graft and patient survival in both groups. Plasma levels of TNF alpha, IFN gamma, IL-6, and IL-8 increased as predicted following OKT3 administration, without significant differences between PTF and placebo groups. In this controlled, multicenter trial, pretreatment with oral PTF was ineffective in attenuating OKT3-related CRS in renal allograft recipients. 相似文献
23.
L Kabasakal BD Collier R Shaker RS Hellman S Smart K Ozker AZ Krasnow AT Isitman 《Canadian Metallurgical Quarterly》1996,37(8):1285-1288
Twenty-six patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel, 250 mg/m2 over 3 h every 21 days. They received steroid, H1 and H2 blocker premedications, and granulocyte-colony-stimulating factor (G-CSF) support (5 microgram/kg/day). No prior chemotherapy, except as a radiation sensitizer, was allowed. The median age was 50 (range, 36-81) years, and performance status Zubrod was 1 (range, 0-2). Eight (33%) patients had prior surgery, and 22 (92%) had prior radiation therapy. Twenty-four patients were evaluable for response; 2 were later found to be ineligible. Five patients had partial responses (21%; 95% confidence interval, 6-40%), and 14 (58%; 95% confidence interval, 35-78%) had stable disease. The median duration of response was 10 (range, 3-27+) weeks. The responses were within the radiation port (four responses) and outside of it (one response). The median interval from the start of irradiation to the start of paclitaxel in responding patients was 94 weeks, whereas in patients with stable disease it was 68 weeks, and in patients whose disease progressed it was 46 weeks. Eighty-eight percent of the 105 cycles of paclitaxel were administered at a dose of 250 mg/m2 or higher. Granulocytopenia was brief and noncumulative, with grades 3 and 4 experienced by 5 and 3 patients, respectively. G-CSF was used for a median of 7 (range, 2-14) days/cycle. Anemia was mild, with G3 noted in 3 patients, and thrombocytopenia was not significant. Infections and musculoskeletal pain were mild and infrequent. Sensory (14 patients G1 or G2 and 2 patients G3) and motor (4 patients G1 or G2 and 1 patient G3) neurotoxicity was noted. There was no significant cardiovascular toxicity. Paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated at this dose schedule with G-CSF support. 相似文献
25.
Freeman-Sheldon's syndrome is a rare genetic disease inherited as an autosomal dominant trait in some families but showing sporadic appearance in the majority of the reported cases. In the present paper we report a family having two affected children from normal consanguineous parents suggesting that Freeman-Sheldon's syndrome may be heterogeneous from the genetic point of view. 相似文献
26.
27.
28.
RS Sherwin W Tamborlane R Hendler L Saccá RA DeFronzo P Felig 《Canadian Metallurgical Quarterly》1977,45(5):1104-1107
Somatostatin was infused for 6 h into seven normal subjects with and without a replacement dose of glucagon. The addition of glucagon to somatostatin resulted in a 30-40% rise in plasma glucagon, whereas plasma insulin declined by 40-50% in both treatment groups. Plasma glucose and glucose production initially increased 2-fold with glucagon replacement, and subsequently declined by 2-3 h to levels comparable to those observed with somatostatin alone. After 6 h plasma glucose and glucose kinetics were no different whether or not glucagon was present. The rise in blood ketones after somatostatin was not exaggerated by glucagon replacement. We conclude that glucagon lack is not a modifying factor in the late hyperglycemic and hyperketonemic response to prolonged infusions of somatostatin. 相似文献
29.
30.